For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$38.17
Thesis
Novo Nordisk markets the semaglutide products Ozempic and Wegovy for type 2 diabetes and obesity. As a diversified company, its incretin franchise sits alongside a broader diabetes and metabolic portfolio.
Catalysts
- Semaglutide supply and manufacturing expansion
- Next-generation incretin clinical readouts
- Label expansions for Ozempic and Wegovy
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Sep 22Trial initiationClinicalTrials.gov
Phase 3 trial (NCT07207811) of Coramitug initiated in ATTR amyloidosis heart failure; recruiting status.
- Sep 21Trial readoutClinicalTrials.gov
Phase 2 trial NCT06326047 of NN0519-0130 in Type 2 diabetes completed (status update 2026-09-21).
- Sep 18Trial initiationClinicalTrials.gov
Phase 3 trial NCT06609226 initiated for long-term Etavopivat in sickle cell disease or thalassemia (recruiting status).
- Sep 17Trial initiationClinicalTrials.gov
Novo Nordisk initiates Phase 3 trial NCT06612268 evaluating Etavopivat in sickle cell disease; status recruiting.
- Sep 16Trial initiationClinicalTrials.gov
Phase 3 trial NCT07822061 (AMAZE 10) for NNC0487-0111 recruiting in Japan for excess body weight.
- Sep 15Trial initiationClinicalTrials.gov
Novo Nordisk updates NCT07658417 to ENROLLING_BY_INVITATION: study of once-weekly insulin icodec vs daily basal in Type 2 diabetes.
- Sep 14Trial initiationClinicalTrials.gov
Phase 3 trial NCT07817251 initiated (not yet recruiting) to study switching from semaglutide to Cagrisema in type 2 diabetes.
- Sep 11Trial initiationClinicalTrials.gov
Phase 3 trial NCT07571005 recruiting for NNC0487-0111 in excess body weight and obstructive sleep apnoea.